163 related articles for article (PubMed ID: 12092692)
1. Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
Barry M; Heerey A
Ir Med J; 2002 May; 95(5):133-5. PubMed ID: 12092692
[No Abstract] [Full Text] [Related]
2. Statins for cardiovascular prevention according to different strategies: a cost analysis.
Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
Walshe V; Nash A; Barry M
Ir Med J; 2006 May; 99(5):144-5. PubMed ID: 16892920
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of statins in coronary heart disease.
Franco OH; Peeters A; Looman CW; Bonneux L
J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
Fidan D; Unal B; Critchley J; Capewell S
QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
7. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of coronary heart disease prevention].
Wendland G; Klever-Deichert G; Lauterbach K
Z Kardiol; 2002; 91 Suppl 2():49-60. PubMed ID: 12436765
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
11. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
[TBL] [Abstract][Full Text] [Related]
12. Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.
Ann Intern Med; 2006 Mar; 144(5):I29. PubMed ID: 16520469
[No Abstract] [Full Text] [Related]
13. Using statins to treat 'healthy' patients: are we there yet?
Shah BM; Kemp R; Clearfield M
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):103-5. PubMed ID: 19402795
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
16. Primary prevention of coronary heart disease with statins: it's not about the money.
Schwartz JS
Circulation; 2011 Jul; 124(2):130-2. PubMed ID: 21747064
[No Abstract] [Full Text] [Related]
17. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
Lindgren P; Jönsson B; Yusuf S
J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
Lazar LD; Pletcher MJ; Coxson PG; Bibbins-Domingo K; Goldman L
Circulation; 2011 Jul; 124(2):146-53. PubMed ID: 21709063
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: Statin use in the elderly.
Raffel OC; White HD
Nat Clin Pract Cardiovasc Med; 2006 Jun; 3(6):318-28. PubMed ID: 16729010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
